A phase II open label multicenter study to assess the efficacy and safety of AFM13 in patients with relapsed or refractory CD30 positive peripheral T cell lymphoma or transformed mycosis fungoides (REDIRECT)
Harstrick et al.
ASCO 2020 - AFM13
Harstrick et al.
ASCO 2020 - AFM13
Ellwanger et al.
NK2019 - ROCK®
Marin et al.
NK2019 - AFM13
Ellwanger et al.
mAbs 2019; 11:899-918.
Sawas et al.
15-ICML - AFM13
Duell et al.
J Immunother 2019; 42:180-188.
Kluge et al.
AACR 2019 - AFM24
Marin et al.
AACR 2019 - AFM13
Bartlett et al.
ASH 2018 - AFM13-103
Wingert et al.
ASH 2018 - Macrophages